BioSpace News Archive

Medivir AB announces that an abstract about its lead program fostroxacitabine bralpamide and the potential efficacy in primary liver cancer has been accepted for presentation at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, USA.

AbbVie announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium 2022, taking place in London from September 8-11.

Scopio Labs, developer of Full-Field Cell Morphology™ imaging and AI-powered analysis platforms to support laboratory professionals in the detection of cancers, anemia, infections, and other blood-related diseases, announced the launch of the Full-Field Bone Marrow Aspirate™ Application.

Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company committed to the development of novel class antibiotics, revealed its involvement in three panel discussions at the World AMR Congress, taking place in Fort Washington, Maryland, from September 7th – 8th.

AlzeCure Pharma AB announced that the United States Patent Office has issued a patent covering ACD856, which is being developed against Alzheimer’s disease and other disorders with cognitive impairment.

An analysis from AbbVie’s three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.

ITM Isotope Technologies Munich SE announced the signing of a global cooperation framework agreement to support the development and use of targeted radiopharmaceuticals for cancer diagnostics and treatment.

Burning Rock Biotech Limited announced that all shareholder resolutions proposed at the Company’s 2022 annual general meeting held today were duly passed.

Cardior Pharmaceuticals announced the CE marking of its PCR kit which measures circulating microRNA-132 levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor.

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a fireside chat on Wednesday, September 14, 2022, at the Morgan Stanley 20th Annual Global Healthcare Conference, in New York, NY.